NASDAQ · PKBOW
Peak Bio, Inc.
Healthcare · Biotechnology
$0.01
Up+$0.01 (+4850.00%)
Updated Sep 12, 2026, 1:16 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 531.87K
- P/E ratio
- -0
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 10K
- Avg. volume
- 0
Price performance
PKBOW price history
1M range · 0 trading sessions · Daily adjusted prices
PKBOW does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest PKBOW news
The latest Smart Investors Daily articles mentioning PKBOW.
Stock researchCompany · Overview
PKBOW research
Overview
Company profile and research snapshot.
Company profile
Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company is based in Palo Alto, California.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
